Status:
COMPLETED
A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809
Lead Sponsor:
GlaxoSmithKline
Conditions:
Substance Dependence
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
GSK598809 is being developed to facilitate overcoming an addiction to nicotine and to help people stop smoking. This study will investigate if GSK598809 is safe and tolerated in people who smoke and w...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Healthy adult male smoker between the ages of 18 and 50 years
- Body weight greater than 50kg and BMI between 18.5-29.9 kg/m2.
- No abnormalities on the medical, psychiatric or laboratory evaluation
- Smoke on average more than 20 but less that 40 cigarettes per day for the past year and not tried to give up in the 3 months before the study.
- Exclusion criteria:
- History of psychiatric disorder or sleep disorder.
- Receiving treatment for smoking cessation.
- Use tobacco products other than cigarettes.
Exclusion
Key Trial Info
Start Date :
March 20 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 20 2007
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00437840
Start Date
March 20 2007
End Date
June 20 2007
Last Update
August 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Berlin, Germany, 13251